Arcturus Therapeutics (ARCT) vs Enanta Pharmaceuticals (ENTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Arcturus Therapeutics (ARCT) over the past year, gaining 11.6% versus a loss of 37.6%. Over five years, ARCT leads with a -72.0% price change compared with -82.7% for ENTA. Arcturus Therapeutics is the larger company by market cap ($362.8 million vs $360.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARCT | ENTA |
|---|---|---|
| Share price | $12.77 | $12.37 |
| Market cap | $362.82M | $360.28M |
| 1-day change | -1.81% | +1.64% |
| YTD return | +108.24% | -21.56% |
| 1-year return | -37.64% | +11.64% |
| 5-year return | -71.98% | -82.69% |
| EPS (TTM) | $-3.33 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.17 | $17.15 |
| 52-week low | $5.50 | $10.20 |
| Distance from 52-week high | -47.19% | -27.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +81.75% | +76.48% |
| Average volume | 938.55K | 226.58K |
| Shares outstanding | 28.42M | 29.13M |
| Employees | 106 | 120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed ARCT by 49.3 percentage points over the past year.
About Arcturus Therapeutics
ARCT stock →Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
ARCT vs ENTA FAQ
Which is bigger, Arcturus Therapeutics or Enanta Pharmaceuticals?
Arcturus Therapeutics (ARCT) is larger, with a market capitalization of $362.82M compared with $360.28M for Enanta Pharmaceuticals (ENTA).
Which stock has performed better over the past year, ARCT or ENTA?
ENTA returned +11.64% over the past 12 months, compared with -37.64% for ARCT (price return, excluding dividends). Past performance does not predict future results.
Are Arcturus Therapeutics and Enanta Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.